文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性患者接受雷珠单抗或贝伐珠单抗治疗1年和2年后低视力的风险

RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2017-01-01

基于瑞典黄斑登记处2011至2014年3912例新生血管性年龄相关性黄斑变性患者数据,分析雷珠单抗或贝伐珠单抗治疗后的视力结局。治疗结局取决于首次就诊时视力:初始视力超过60个字母者治疗1年或2年后视力低于60个字母的风险约20%,而初始视力低于60个字母者风险约60%;该风险与药物选择无关。结论为抗血管内皮生长因子玻璃体腔注射主要维持视力水平,治疗1年和2年后分别仅约20%和40%的患者需要视力康复。

要点

  • 初始视力超过60个字母者,治疗1年或2年后视力低于60个字母的风险约20%。
  • 初始视力低于60个字母者,治疗1年或2年后视力低于60个字母的风险约60%。
  • 视力低于60个字母的风险与选择雷珠单抗或贝伐珠单抗无关。

核心结论

  • 抗血管内皮生长因子玻璃体腔注射治疗主要维持视力水平,治疗1年和2年后分别仅约20%和40%的患者需要视力康复。

研究设计与样本

  • 基于瑞典黄斑登记处2011至2014年3912例接受雷珠单抗或贝伐珠单抗治疗的新生血管性年龄相关性黄斑变性患者的数据。

主要发现

  • 治疗结局取决于首次就诊时视力:初始视力超过60个字母者,治疗1年或2年后视力低于60个字母的风险约20%。
  • 初始视力低于60个字母者,治疗1年或2年后视力低于60个字母的风险约60%。
  • 视力低于60个字母的风险与选择雷珠单抗或贝伐珠单抗无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. METHODS: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years. RESULTS: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug. CONCLUSION: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Westborg I, Albrecht S, Rosso A, et al. RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2017. PMID: 28141748. doi:10.1097/IAE.0000000000001431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。